Crossmark

Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis

Crossref DOI link: https://doi.org/10.1186/s12885-018-4011-8

Published: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Shunli

Peng, Hong

Wang, Ye

Xu, Ming

Lin, Manxia

Xie, Xiaoyan

Peng, Baogang

Kuang, Ming
Funding

Funding for this research was provided by:

Natural Science Foundation of Guangdong Province (2014A030313108)

National Natural Science Foundation of China (81071892, 81272312)

the Fundamental Research Funds for the Central Universities (15ykpy15, 09ykpy30)

the Science and Technology Project of Guangzhou (2014Y2-00129)
More Information

Article History

Received: 4 October 2016

Accepted: 21 January 2018

First Online: 31 January 2018

Ethics approval and consent to participate

: This study was performed according to the guidelines of the Helsinki Declaration. It was registered and approved by the ethics committee at The First Affiliated Hospital of Sun Yat-sen University. All patients provided written informed consent before treatment.

: N/A.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.